Searched for
SPORLAC
JB Pharma Q3 net profit jumps 22% to Rs 162 croreJB Pharma on Tuesday reported a 22% year-on-year (Y-o-Y) jump in net profit to Rs 162 crore for the quarter ended December 31 led by strong...- JB Pharma Q2 Results: Net profit jumps 16% to Rs 175 crore, revenue up 13%JB Pharma reported a 16% YoY increase in Q2FY25 net profit to Rs 175 crore, driven by 22% growth in domestic business. Revenues rose 13% to...
- JB Pharma Q1 Results: Net profit jumps 25% YoY to Rs 177 croreThe drug maker had reported a net profit of Rs 142 crore in the year-ago period.Revenue for the quarter rose 12% YoY to Rs 1004 crore
- JB Pharma open to more buys to grow branded biz shareJB Chemicals & Pharmaceuticals (JB Pharma), controlled by US private equity firm KKR, is evaluating assets for acquisitions to strengthen i...
- JB Pharma acquires rosuvastatin brand from Glenmark for Rs 314 croreThe acquisition will be funded through long term debt and internal accruals. Razel ranks among the top 10 brands in India in the rosuvastat...
- JB Pharma net profit down 12% to Rs 105 croreThe company reported net profit of Rs 119 crore during corresponding period of the previous year.The company attributed the drop in net pro...
- JB Chemicals to acquire brands from Sanzyme for Rs 628 croreJB Chemicals and Pharmaceuticals Ltd on Thursday said it will acquire brands for the Indian market from Sanzyme Pvt Ltd, a player in the pr...
- JBCPL to buy probiotic and reproductive brands from Sanzyme for Rs 628 croreThe acquired portfolio includes Sporlac which is the third largest probiotics brand in India and specialized products such as Lobun - a pro...
Load More